CD274 and neoplasm: In summary, the camrelizumab-anlotinib combination effectively overcame three critical therapeutic barriers: primary immunotherapy resistance (PD-L1-Low), inadequate tumor immunogenicity (TMB-Low/MSS), and profound oncogenic complexity.